The EU butts heads with Big Pharma to make medicines cheaper

By HEOR Staff Writer

February 2, 2023

EU Pharmaceutical Regulations Proposal

The new EU proposal to revamp its pharmaceutical regulations. The main aim is to give people a better and more affordable access to medicines.

From what I can see, there are mixed feelings about the proposal. On one hand, consumer groups and civil society organizations are applauding the EU’s efforts to make medicines more accessible. On the other hand, the pharmaceutical industry is a bit skeptical.

So, what’s in the proposal? Well, the EU is looking to shorten the period in which pharmaceutical companies can sell their medicines without competition from 10 years to just 8 years. They’re also working towards closing the gap in access to medicines among different EU member states.

It’s interesting to see how this will all play out. What are your thoughts on the EU Pharmaceutical Regulations Proposal?

Reference url

Recent Posts

generative AI diagnosis
Generative AI Diagnosis in Neurology Enhances Non-Specialist Accuracy

By João L. Carapinha

June 5, 2026

Generative AI diagnosis is stepping into neurology with striking results. In a new study, ChatGPT-4o reached 65.5% accuracy for the correct leading diagnosis in challenging polyneuropathy cases, statistically matching non-specialist neurologists (63%) while trailing specialists (74%). The model o...
Mirvetuximab ovarian cancer
NICE Guidance on Mirvetuximab Ovarian Cancer Treatment

By HEOR Staff Writer

June 5, 2026

Mirvetuximab ovarian cancer treatment has taken a major step forward after NICE recommended mirvetuximab soravtansine for adults with folate receptor-alpha positive, platinum-resistant high-grade serous epithelial ovarian, fallopian tube or primary peritoneal cancer who have received one to three...
biosimilar policy development
Multistakeholder Engagement in Biosimilar Policy Development

By João L. Carapinha

June 3, 2026

In advancing biosimilar policy development across Europe, the AUGMENT Biosimilars project identifies effective measures to overcome barriers to uptake, lower costs, and expand patient access to follow-on biological medicines. The three-day